Caplin Point Laboratories Limited — Updates, 26-02-2025: Press Release

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories, has received final approval from the USFDA for its generic eye drops, Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution (0.2%/0.5%) in multiple presentations. This product serves as a therapeutic equivalent to Abbvie's COMBIGAN and targets the reduction of intraocular pressure in glaucoma and ocular hypertension patients. The US market for this medication generated approximately $242 million in sales for the 12 months ending December 2024, marking a significant opportunity for Caplin. The company has a robust pipeline, having filed 46 ANDAs in the US, with 34 approvals thus far, and continues to expand its portfolio of injectable and ophthalmic products aimed at fulfilling growing demands in both the US and international markets. This FDA approval is poised to enhance Caplin's market position and revenue growth, signaling a positive outlook for stakeholders.